PMID: 8970247Nov 1, 1996Paper

Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension

Survey of Ophthalmology
J Schuman

Abstract

The ocular hypotensive efficacy and safety of brimonidine tartrate 0.2%, a highly selective alpha 2-adrenergic agonist, was compared with that of timolol 0.5%, a nonselective beta-blocker in two multicenter, randomized, double-masked studies. Combined data from a 12-month completed study and 6-month interim data from an ongoing study are reported. Efficacy and safety were evaluated at baseline, weeks 1 and 2, and months 1, 2, 3, 6, 9, and 12. Intraocular pressure (IOP) was measured at peak (2 hours after the morning dose) and trough (12 hours after the evening dose). Patients (n = 926) instilled either brimonidine tartrate 0.2% or timolol maleate 0.5% twice daily. At peak, the mean decreases from baseline IOP ranged from 5.9 +/- 3.2 mm Hg to 7.6 +/- 3.6 mm Hg for brimonidine and 6.0 +/- 3.4 mm Hg to 6.6 +/- 3.6 mm Hg for timolol (p < 0.001 within groups compared with baseline). No significant between-group differences were seen at peak except for weeks 1 and 2 and month 3 (p < or = 0.04), when brimonidine had lower mean IOP. At trough the mean decreases from baseline ranged from 3.7 +/- 4.0 mm Hg to 5.0 +/- 3.0 mm Hg for brimonidine and 5.9 +/- 3.4 to 6.6 +/- 3.0 for timolol. A significant between-group difference was seen at t...Continue Reading

References

Jan 15, 1991·American Journal of Ophthalmology·M WilkersonM B Shields

❮ Previous
Next ❯

Citations

Oct 6, 2000·American Journal of Ophthalmology·D B BylesJ F Salmon
May 20, 1999·American Journal of Ophthalmology·D H ShinK D Nguyen
Sep 11, 1999·American Journal of Ophthalmology·C B TorisM E Yablonski
Sep 3, 2002·Survey of Ophthalmology·Philip F J Hoyng, Yoshi Kitazawa
Nov 1, 1996·Survey of Ophthalmology·J T Wilensky
Apr 12, 2001·Ophthalmology·A R KentD Fellows
Jan 4, 2003·Ophthalmology·Carl B Camras
Jan 29, 2003·Journal of Cataract and Refractive Surgery·Frederick W Fraunfelder, Larry F Rich
Oct 23, 2002·Acta Ophthalmologica Scandinavica. Supplement·L TavernitiUNKNOWN Donati
Oct 29, 1998·The New England Journal of Medicine·W L Alward
Mar 22, 2003·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Tom MundorfAmy Batoosingh
Aug 25, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·E Randy CravenUNKNOWN Combigan Study Group
Jul 1, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Ho Yeop YeomGong Je Seong
Sep 29, 2007·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Chan Yun KimGong Je Seong
Jul 27, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Michael Sullivan-MeeClifford Qualls
May 9, 2012·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Naveed NilforushanKouros Nouri-Mahdavi
Aug 26, 1998·Australian and New Zealand Journal of Ophthalmology·W E Gillies, A M Brooks
Apr 26, 2003·The British Journal of Ophthalmology·A HommerUNKNOWN Unoprostone Adjunctive Therapy Study Group
Mar 25, 2008·Therapeutics and Clinical Risk Management·Robert J Noecker
Jun 23, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Michele VetrugnoCarlo Sborgia
Sep 25, 2015·Ocular Immunology and Inflammation·Jacqueline Beltz, Ehud Zamir
Apr 29, 2011·Experimental Eye Research·Stella Arthur, Louis B Cantor
Nov 1, 1996·Survey of Ophthalmology·J Burke, M Schwartz
Mar 27, 2004·Acta Ophthalmologica Scandinavica·William C StewartJessica Jenkins
May 23, 2008·Acta Ophthalmologica·William C StewartBonnie Kruft
Aug 11, 2015·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Verena Ribeiro JuncalTiago Santos Prata
Apr 7, 2010·Expert Opinion on Drug Safety·Mamun Q RahmanDonald M I Montgomery
Jun 13, 2002·Acta Ophthalmologica Scandinavica·William C StewartAngi L Jackson
Jan 1, 2012·Ophthalmology and Eye Diseases·Laura CrawleyLi Guo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.